Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2003 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00042913
First received: August 5, 2002
Last updated: December 18, 2013
Last verified: September 2003

August 5, 2002
December 18, 2013
May 2002
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00042913 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
A Phase 2 Open Label, Randomized, Dose And Schedule Finding, Clinical Trial Of Immunotherapy With AMG 412 In Subjects With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.

PURPOSE: Randomized phase II trial to study the effectiveness of epratuzumab in treating patients who have non-Hodgkin's lymphoma.

OBJECTIVES:

  • Determine the response rate of patients with diffuse large B-cell non-Hodgkin's lymphoma treated with epratuzumab.
  • Determine the toxicity of this drug in these patients.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 3 treatment arms.

  • Arm I: Patients receive low-dose epratuzumab IV over 1 hour once weekly for 4 weeks.
  • Arm II: Patients receive low-dose epratuzumab IV over 1 hour once weekly for 8 weeks.
  • Arm III: Patients receive high-dose epratuzumab IV over 1 hour once weekly for 4 weeks.

Patients are followed every 3 months for 2 years and then every 6 months thereafter.

PROJECTED ACCRUAL: A total of 150 patients (50 per treatment arm) will be accrued for this study.

Interventional
Phase 2
Allocation: Randomized
Primary Purpose: Treatment
Lymphoma
Biological: epratuzumab
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
Not Provided
Not Provided
Not Provided

DISEASE CHARACTERISTICS:

  • Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma (NHL)

    • Relapsed or refractory after at least 1 regimen of standard therapy

      • Prior therapy may include high-dose chemotherapy with autologous stem cell transplantation (ASCT) or immunotherapy
  • Bidimensionally measurable disease

    • At least 1 lesion at least 1.5 cm by CT scan
  • No primary or secondary CNS lymphoma
  • No HIV-related lymphoma
  • No known or suspected transformed lymphoma (prior or concurrent)
  • No bulky disease (i.e., any single mass greater than 10.0 cm)
  • No pleural effusion with positive cytology for lymphoma
  • Most recent pathology specimen available for collection
  • No rapid disease progression or symptoms that indicate disease progression requiring rapid intervention within the past 2 weeks (e.g., severe shortness of breath, severe pain, or gastrointestinal or genitourinary obstruction)

PATIENT CHARACTERISTICS:

Age

  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 4 months

Hematopoietic

  • Absolute neutrophil count at least 1,000/mm3
  • Platelet count at least 50,000/mm3 (transfusion independent)
  • Hemoglobin at least 9.0 g/dL

Hepatic

  • Bilirubin no greater than 2 times upper limit of normal (ULN)
  • AST and ALT less than 5 times ULN
  • Hepatitis B surface antigen negative
  • Hepatitis C negative

Renal

  • Creatinine no greater than 2 times ULN

Other

  • HIV negative
  • No other primary malignancy within the past 3 years except squamous cell or basal cell skin cancer, carcinoma in situ of the cervix, or stage I prostate cancer
  • No other serious nonmalignant condition that would preclude study
  • No serious infection
  • No known human antichimeric antibodies or human antihuman antibody positivity
  • No type 1 hypersensitivity or anaphylactic reactions to murine proteins
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for at least 6 months after study

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Disease Characteristics
  • At least 4 weeks since prior immunotherapy (unless clearly progressing)
  • At least 12 weeks since prior ASCT

Chemotherapy

  • See Disease Characteristics
  • At least 4 weeks since prior chemotherapy (unless clearly progressing)

Endocrine therapy

  • Not specified

Radiotherapy

  • No prior radioimmunotherapy

Surgery

  • At least 4 weeks since prior major surgery (unless patient has fully recovered)

Other

  • At least 30 days since prior enrollment in clinical trials involving investigational devices or drugs
  • No concurrent enrollment in other clinical trials involving investigational devices or drugs
  • No concurrent investigational agents for disease other than NHL
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00042913
CDR0000069484, UCLA-0201056, AMGEN-AMG-412-159, NCI-G02-2094
Not Provided
Not Provided
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
Principal Investigator: Christos E. Emmanouilides, MD Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
September 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP